mechanism of glp 1 receptor agonists Mechanisms action of GLP-1RA Possible mechanisms of action of
Description
also reported a low risk of hypoglycemia, with events occurring in similar proportions of patients with obesity but without diabetes who were treated with liraglutide 3.0 mg (1.3%) compared with placebo (1.0%) [37]

Special considerations: children and adolescents Several GLP-1RAs, including liraglutide and dulaglutide, are approved for treating children and adolescents with type 2 diabetes

There are a large number of studies that have reported the application of exendin-4, liraglutide and exenatide in the treatment of cognitive dysfunction and pathological features in AD models

DeFronzoRALewinAPatelSLiuDKasteRWoerleHJet al

Diabetes and prediabetes

Liraglutide Liraglutide, trade name Victoza, was developed by Novo Nordisk
